The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

Participants in the study will receive the combination treatment over a period of up to 24 weeks. During this time, researchers will monitor the participants to see if they can achieve a transfusion independence (TI) response, meaning they do not need blood transfusions for a certain period. The study will also track any side effects or changes in health that may occur during the treatment. The goal is to understand if this combination can improve the quality of life for those with transfusion-dependent Myelofibrosis.

The study is open-label, which means both the participants and the researchers know which treatments are being administered. This trial aims to provide valuable insights into the potential benefits of using Momelotinib and Luspatercept together for managing Myelofibrosis and reducing the need for blood transfusions. The findings from this study could help in developing better treatment strategies for patients with this condition.

The purpose of the study is to determine if low-dose DOACs are more effective than low-dose Aspirin in preventing blood clots in high-risk patients with these blood disorders. Participants in the study will be randomly assigned to receive either Apixaban, Rivaroxaban, or Aspirin. The study will monitor the time it takes for any blood clotting events to occur, as well as any significant bleeding events. The study will also look at other health outcomes, such as overall survival and quality of life, over a period of 24 months.

Throughout the study, participants will take their assigned medication orally, and their health will be closely monitored by the research team. The study will help to better understand which medication is more effective in preventing complications related to blood clots in patients with these specific blood disorders. The findings could lead to improved treatment options for individuals with these conditions.

The purpose of the study is to determine the best dose of KRT-232 when used with Ruxolitinib and to see if this combination can reduce the size of the spleen, an organ that can become enlarged in these conditions. The study will involve regular check-ups and assessments to monitor the safety and effectiveness of the treatment. Participants will take the medications and have their spleen size measured at various points during the study, including at the 24-week mark. The study will also look at other factors, such as changes in symptoms and the need for blood transfusions.

This trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s impact over time. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

Participants in the study will be randomly assigned to receive either Navtemadlin or the best available therapy, which is the most effective treatment currently available for their condition. The study will last for several weeks, and during this time, doctors will monitor the size of the spleen using imaging techniques like magnetic resonance imaging (MRI) or computed tomography (CT) scans. The study will also look at other factors, such as the symptoms experienced by participants and their need for blood transfusions.

The study aims to provide valuable information about the effectiveness of Navtemadlin in treating myelofibrosis, especially for those who have not had success with JAK inhibitors. By comparing the new treatment with existing therapies, researchers hope to find better ways to manage this challenging condition. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on how the treatment affects their health.

The purpose of this study is to evaluate the long-term safety of luspatercept, including monitoring for any progression to more serious conditions such as acute myeloid leukemia (AML) or the development of other types of cancer. Participants in this study will receive luspatercept as a solution for injection, which is administered under the skin. The study is designed as an open-label, single-arm, rollover study, meaning all participants will receive the treatment without a comparison group receiving a placebo.

Throughout the study, participants will be monitored for any adverse events or changes in their condition. The study will also track overall survival and any new growths that may develop. The maximum treatment period for participants is up to 360 days, during which they will continue to receive the treatment and be regularly assessed by healthcare professionals. This study aims to provide valuable information on the long-term effects and safety of luspatercept for individuals with these blood disorders.

The purpose of the study is to compare the effectiveness and safety of luspatercept with a placebo in adults who are already receiving a type of medication called a JAK2 inhibitor as part of their standard treatment. Participants in the study will receive either luspatercept or a placebo, and their progress will be monitored over a period of time to see if they can become free from needing red blood cell transfusions for at least 12 weeks.

Throughout the study, participants will continue their usual treatment with the JAK2 inhibitor while receiving the study medication. The trial aims to provide valuable information on whether luspatercept can offer a significant benefit in managing anemia in patients with myelofibrosis, potentially improving their quality of life by reducing the frequency of blood transfusions needed.

The study is divided into two phases. In the first phase, the focus is on determining the safety of tasquinimod and finding the right dose that can be used in the second phase. The second phase aims to evaluate how well tasquinimod works in reducing the size of the spleen, which is often enlarged in patients with myelofibrosis. This is measured using imaging techniques like MRI or CT scan after 24 weeks of treatment.

Participants in the study will take tasquinimod once daily and will be monitored for any side effects and changes in their condition. The study will also look at other outcomes, such as overall survival, changes in symptoms, and the need for blood transfusions. The trial is expected to continue until 2030, with recruitment starting in 2024.

The purpose of the study is to evaluate how effective this combination therapy is for patients with Myelofibrosis who have not responded well to previous treatments known as JAK-inhibitors. Participants in the study will receive the combination of Fedratinib and Nivolumab over a period of time, and their response to the treatment will be monitored. The study will look at various outcomes, such as the improvement in symptoms, the need for blood transfusions, and overall quality of life.

Throughout the study, the safety of the treatment will be closely observed, including any side effects that may occur. The trial will also assess how the treatment affects the progression of the disease and the overall survival of the participants. This research aims to provide valuable insights into the potential benefits of combining Fedratinib and Nivolumab for treating Myelofibrosis.

The purpose of the study is to determine how well selinexor works compared to the physician’s choice in patients who have already received treatment for myelofibrosis. The study will involve regular check-ups and assessments to monitor the effects of the treatment. Participants will be randomly assigned to one of the two treatment groups and will continue with their assigned treatment for a specified period. The study will also look at how the treatment affects symptoms and overall health, including any changes in spleen size, which is often enlarged in myelofibrosis.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on the potential benefits of selinexor for patients with myelofibrosis, helping to guide future treatment options. The trial is designed to ensure the safety and well-being of all participants while gathering important data on the effectiveness of the treatment.

The purpose of the study is to evaluate how well Pacritinib works in reducing the size of the spleen and improving symptoms in patients with myelofibrosis. The study will last for a period of 24 weeks, during which patients will receive either Pacritinib or one of the physician’s choice therapies. Throughout the study, patients will undergo regular assessments, including imaging tests like MRI or CT scans, to measure changes in spleen size and symptom severity. The study aims to determine if Pacritinib can achieve a significant reduction in spleen volume and improve the overall symptom score compared to the other treatments.

Participants in the study will be monitored for any side effects or adverse events, and their overall health will be assessed through various tests and evaluations. The study will also track the time it takes for any significant health changes to occur, such as improvements in symptoms or any serious health issues. The trial is expected to provide valuable information on the effectiveness and safety of Pacritinib for patients with severe thrombocytopenia due to myelofibrosis.